Cyproheptadine

Evidence Level: L5

Predicted Indications: 1

Cyproheptadine

Pharmacist Assessment Report

Cyproheptadine: H1 antihistamine (serotonin antagonist) → nasal cavity disease

One-Sentence Summary

Cyproheptadine is an antihistamine that is marketed in Canada as single-ingredient products. The TxGNN model predicts it may be useful for nasal cavity disease, but the data compiled for this report contain no clinical trials and no publications on this condition, so the prediction rests on the model alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	nasal cavity disease
TxGNN Prediction Score	0.9921
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 3 of 3)
Number of DINs	3 (marketed: 3)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on general class knowledge, cyproheptadine is a first-generation H1 antihistamine, and blocking histamine receptors is relevant to conditions that involve nasal inflammation and congestion.

“Nasal cavity disease” is a broad, non-specific term. It covers many conditions, including allergic and vasomotor problems of the nose, which are close to the conditions this drug is already used for. The prediction therefore adds no new, specific disease entity. With no trials or publications in the data, the link rests on the model score and class pharmacology only, and should be treated as a hypothesis.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02332248	JAMP-CYPROHEPTADINE	Not recorded	Not recorded in local data
02533065	MAR-CYPROHEPTADINE	Not recorded	Not recorded in local data
02466732	EURO-CYPROHEPTADINE 2MG/5ML	Not recorded	Not recorded in local data

All three licences are for single-ingredient products and are currently valid.

Safety Considerations

Drug Interactions: 100 interacting drugs were identified. Two are rated Major: potassium citrate and potassium chloride. Most others are rated Moderate, including anticholinergics (atropine, hyoscyamine, scopolamine, glycopyrronium, dicyclomine, trospium), opioids and related agents (morphine, loperamide, opium, eluxadoline), cannabinoids (dronabinol, nabilone), metoclopramide and fenfluramine.

Please refer to the package insert for warnings and contraindications, which were not available in the data compiled for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The only support is a high model score. No trial or publication directly studies this condition, so the evidence level is L5. The predicted term is also too broad to guide a development plan.

To proceed, the following is needed:

A more specific target condition (for example, a defined type of rhinitis or sinonasal disease) in place of the broad term
Clinical or preclinical studies directly addressing that condition
Mechanism of action data
Health Canada package insert warnings and contraindications for the safety review
Confirmation of dosage forms and routes for the marketed products
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.